Spruce Biosciences, Inc. (SPRB) Stock Price & Analysis
Spruce Biosciences, Inc. (SPRB) closed at USD 41.47 on Thursday, October 15, 2026, up 6.39% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 38.98; the Oct 15, 2026 session ranged USD 39.11–41.88 on volume of 63,772 shares. Market capitalization is $119.19M, with a 52-week range of USD 38.06–163 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/SPRB.md
Key facts (SPRB)
- Analysts: Buy (mean 1.89 on a 1–5 scale) (9 analysts), mean target USD 148 (range 104–230).
- Total return with dividends: 1Y -73.5% vs S&P 500 +18.1%; 5Y -99.8% vs S&P 500 +85.1%.
Analysts (SPRB)
Consensus Buy (mean 1.89 on a 1–5 scale), 9 analysts; mean target USD 148 (low 104, high 230).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-24 | Citizens | Reiterated | Market Outperform | $144 |
| 2026-09-17 | Lake Street | Initiated | Buy | $149 |
| 2026-08-17 | Guggenheim | Target lowered | Buy | $123 → $104 |
| 2026-08-13 | Citizens | Target lowered | Market Outperform | $150 → $144 |
| 2026-07-13 | B. Riley Securities | Initiated | Buy | $160 |
Total return (dividends reinvested) (SPRB)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -73.5% | -99.8% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -73.6% | -72.2% |
| Volatility (annualized) | 88.7% | 262.0% |
| Max drawdown | -75.3% (Oct 2025→Oct 2026) | -100.0% (Feb 2024→Aug 2025) |
Key Statistics (as of October 16, 2026 at 05:22 UTC)
| Price | USD 41.47 |
|---|---|
| Change | ▲ 6.39% (up) |
| Previous Close | USD 38.98 |
| Open | USD 39.24 |
| Day Range | USD 39.11 – 41.88 |
| 52-Week Range | USD 38.06 – 163 |
| Volume | 63,772 shares |
| Market Cap | $119.19M |
| Exchange | NCM |
Technical Analysis (SPRB)
Nexqual's technical model rates SPRB "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:22 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 33.68 (neutral) |
| vs SMA50 | Below (USD 51.23) |
| MACD | -3.14 (negative) |
Analyst Ratings (SPRB)
Wall Street analysts rate SPRB "Buy" based on 9 analysts, with a mean price target of USD 148 (range USD 104–230), per Nexqual as of October 16, 2026 at 05:22 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 148 |
| High Target | USD 230 |
| Low Target | USD 104 |
| Buy / Hold / Sell | 9 / 0 / 0 |
Earnings (SPRB)
| EPS Estimate | USD -5.51 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -6.68 vs est -6.12 ▼ miss |
| 2026-03-31 | USD -8.94 vs est -6.12 ▼ miss |
| 2025-12-31 | USD -9.58 vs est -9.57 ▼ miss |
| 2025-09-30 | USD -14.58 vs est -12.31 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financials & Fundamentals (SPRB)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -105.98% |
| Debt / Equity | 0.09 |
| Current Ratio | 9.23 |
| Total Cash | $96.30M |
| Total Debt | $7.67M |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financial Health Score (SPRB)
Nexqual rates Spruce Biosciences, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:22 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $96M cash vs $8M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$43M (TTM) |
| Efficiency | Critical — ROE -106%, ROA -40.0% |
Ownership (SPRB)
| Insider Ownership | +3.37% |
|---|---|
| Institutional Ownership | +76.87% |
| Shares Outstanding | 2.87M |
| Float | 2.02M |
| Short % of Float | +15.17% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Leadership (SPRB)
Spruce Biosciences, Inc. is led by Javier Szwarcberg M.D., M.P.H. (age 55), CEO & Director, per Nexqual as of October 16, 2026 at 05:22 UTC.
| CEO & Director | Javier Szwarcberg M.D., M.P.H. (age 55) |
|---|---|
| Executive Chairman | Michael G. Grey (age 72) |
| President & CFO | Samir M. Gharib (age 43) |
| Vice President of Marketing | Eric Jordan |
| Senior Vice President of Clinical Development Operations | Bruno Gagnon BPHARM, M.Sc. (age 56) |
Major Backers & Investors (SPRB)
Notable institutional backers of Spruce Biosciences, Inc. include AIGH Capital Management LLC, Orbimed Advisors LLC., Millennium Management, according to Nexqual as of October 16, 2026 at 05:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| AIGH Capital Management LLC | 44.4% |
| Orbimed Advisors LLC. | 35.52% |
| Millennium Management | 28.59% |
| AWM Investment Company, Inc. | 26.11% |
| Ikarian Capital, LLC | 21.55% |
| Alyeska Investment Group, L.p. | 14.51% |
| Adar1 Capital Management, LLC | 12.03% |
| Fidelity | 8.73% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 41.94% |
| Geode Capital | 12.53% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt